Pharmaceuticals Middle East

Middle East Diabetes Drugs Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Middle East Diabetes Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Route, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Middle East · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $3.25 Bn Placeholder estimate
Estimate 2025 $3.50 Bn 4.5% of the global market
Projected 2034 $6.83 Bn 95% Adds $3.33 Bn over 9 forecast years
CAGR 2025–2034 7.7% Faster than 31% of 183 Pharmaceuticals markets here
Key players 6 +1
  • Middle East is 4.5% of the global market.
  • Among regions, the largest is North America at $40.19 Bn.
  • Fastest growing: Africa at 8.9% a year.
  • Middle East ranks 5th of 6 by size among regions.

Market size projection

Middle East

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$3.33 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Diabetes Drugs Market market size by year, Middle East
YearMarket sizeChange that yearSince 2025
2024 (estimate) $3.25 Bn — —
2025 (base) $3.50 Bn +$250.5 Mn —
2026 (forecast) $3.77 Bn +$269.8 Mn +7.7%
2027 (forecast) $4.06 Bn +$290.5 Mn +16%
2028 (forecast) $4.38 Bn +$312.9 Mn +24.9%
2029 (forecast) $4.71 Bn +$337.0 Mn +34.5%
2030 (forecast) $5.08 Bn +$363.0 Mn +44.9%
2031 (forecast) $5.47 Bn +$390.9 Mn +56.1%
2032 (forecast) $5.89 Bn +$421.0 Mn +68.1%
2033 (forecast) $6.34 Bn +$453.4 Mn +81%
2034 (forecast) $6.83 Bn +$488.3 Mn +95%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Middle East Diabetes Drugs Market Analysis at a glance
Market size, 2025$3.50 Bn placeholder estimate
Forecast, 2034$6.83 Bn placeholder estimate
Growth (CAGR), 2025–20347.7% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDrug class, route and end user (see all)
Key playersNovo Nordisk A/S, Eli Lilly and Company, Sanofi, AstraZeneca, Merck & Co., Inc. and 1 more (see all)
Active clinical trials82 in Middle EastSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Middle East. Retrieved 21 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Middle East Diabetes Drugs Market Analysis Executive Summary

Diabetes drugs lower blood sugar in people with type 1 or type 2 diabetes, including insulin, pills and injectable GLP-1 medicines.

Key segments of the diabetes drugs market include drug class (Insulin, GLP-1 Agonists and SGLT2 Inhibitors) and route (Oral and Injectable).

Bar chart: Middle East Diabetes Drugs market size, 2024–2034, placeholder estimates. $3.25 Bn in 2024, $3.50 Bn in 2025 and $6.83 Bn in 2034, 7.7% CAGR.
Middle East Diabetes Drugs market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Middle East Diabetes Drugs Market Dynamics

Market Growth Drivers

Rising numbers of people with diabetes, a shift to tools that track and deliver treatment automatically, and more insurance cover are driving the diabetes drugs market.

Opportunity

Connected devices, lower-priced sensors and new insulins and pills give the diabetes drugs market room to grow.

Market Restraints

High costs for people without cover, price competition and uneven access to care in low-income countries hold back the diabetes drugs market.

Competitive Landscape for Diabetes Drugs Market in Middle East

The diabetes drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Diabetes Drugs Market in Middle East

Diabetes Drugs in Middle East: rules, payment and research

In some of the countries we cover here, medicines are approved by SFDA (Saudi Arabia)⁠[1], EDE (UAE)⁠[2], Ministry of Public Health (Qatar)⁠[3] and Ministry of Health (Israel)⁠[4]. How care is paid for in some of these countries: free public care and CHI-regulated insurance (Saudi Arabia)⁠[5], mandatory health insurance (UAE)⁠[6], public care and compulsory insurance (Qatar)⁠[3] and four health funds (Israel)⁠[4]. ClinicalTrials.gov lists 82 studies on Diabetes Drugs that are recruiting, active or about to start in Middle East.⁠[7]

[1] Saudi Food and Drug Authority. Checked 14 Nov 2026.

[2] Emirates Drug Establishment. Checked 14 Nov 2026.

[3] Ministry of Public Health, Qatar. Checked 19 Nov 2026.

[4] Israel Ministry of Health. Checked 19 Nov 2026.

[5] Council of Health Insurance. Checked 14 Nov 2026.

[6] Ministry of Human Resources and Emiratisation. Checked 14 Nov 2026.

[7] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Middle East. Retrieved 21 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for diabetes drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Middle East.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Diabetes Drugs right now, from free public sources.

Clinical trials

82 active trials in UAE, Saudi Arabia, Israel, Yemen, Jordan, Lebanon, Qatar, Syria, Palestine and Iraq

Recruiting, about to start, or running now. Counted across the 10 countries we report on in Middle East.

See every trial on ClinicalTrials.gov (opens in a new tab)

Patients

Diabetes (ages 20–79), % of people 20–79 (World Bank)
CountryValueYear
Iraq13.42024
Israel10.12024
Jordan20.52024
Lebanon12.32024
Palestine15.52024
Qatar24.62024
Saudi Arabia23.12024
Syria19.02024
UAE20.72024
Yemen5.52024
Compare every country on the Public Health Dashboard

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 21 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Diabetes Drugs in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Diabetes Drugs market in Middle East?
Placeholder estimate: about $3.50 Bn in 2025, rising to about $6.83 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Diabetes Drugs market in Middle East growing?
Placeholder estimate: about 7.7% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Diabetes Drugs market report cover?
The report splits the market by drug class (Insulin, GLP-1 Agonists, SGLT2 Inhibitors, DPP-4 Inhibitors and more), route (Oral, Injectable) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Diabetes Drugs market?
Key players include Novo Nordisk A/S, Eli Lilly and Company, Sanofi, AstraZeneca, Merck & Co., Inc. and Boehringer Ingelheim GmbH.
What is driving the Diabetes Drugs market?
Rising numbers of people with diabetes, a shift to tools that track and deliver treatment automatically, and more insurance cover are driving the diabetes drugs market.
How many clinical trials on Diabetes Drugs are running in Middle East?
82 studies are recruiting, active or about to start in Middle East, counted across the 10 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Middle East. Retrieved 21 Nov 2026.
How much research is published on Diabetes Drugs?
PubMed lists 213 papers on Diabetes Drugs added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 21 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Middle East

See all

Related on diabetes

See the topic